Source: Public Affairs Email, Congressionally Directed Medical
Research Program (CDMRP), U.S. Army Medical Research & Materiel
Command (USAMRMC), U.S. Department of Defense (DoD)
********************
FY12 Department of Defense Gulf War Illness Research Program Funding
Opportunities
The Fiscal Year 2012 (FY12) Defense Appropriations Act provides $10
million to the Department of Defense Gulf War Illness Research Program
(GWIRP) to support innovative, high-impact research into Gulf War
Illness. The Department of Defense Gulf War Illness Research Program
is administered by the US Army Medical Research and Materiel Command
(USAMRMC) through the Office of Congressionally Directed Medical
Research Programs (CDMRP).
Please inform researchers interested in Gulf War Illness research that
three award mechanisms have been released. FY12 GWIRP program
announcements and general application instructions are available at:
http://cdmrp.army.mil/funding/gwirp.shtml
1) Investigator-Initiated Research Award - Pre-application is due
April 9, 2012Independent investigators at all academic levels are
eligible to apply.
=95 Supports new ideas in basic and clinical developmental research
focusing on Gulf War Illness (GWI).
=95 Preliminary data are not required, and if provided, do not
necessarily have to come from the GWI research field.
=95 Clinical trials are not allowed under this mechanism.
=95 The maximum allowable funding for the entire period of performance
is $600,000 for direct costs.
=95 The maximum period of performance is 3 years.
=95 More cost-effective studies not requesting the full funding amount
are encouraged.
2) Innovative Treatment Evaluation Award - Pre-application is due
April 9, 2012 Independent investigators at all academic levels are
eligible to apply.
=95 Supports exploratory or small-scale studies evaluating potential
treatments not previously studied in GWI.
=95 Pilot Phase II or Phase I/II trial combinations are permitted.
=95 Preliminary data are not required, though proposed studies must be
supported by logical rationale.
=95 The maximum allowable funding for the entire period of performance
is $450,000 for direct costs.
=95 The maximum period of performance is 3 years.
=95 More cost-effective studies not requesting the full funding amount
are encouraged.
3) Clinical Trial Award - Pre-application is due April 9, 2012
Independent Investigators at all academic levels Supports larger, more
definitive Phase II or III clinical trials focusing on treatments for
GWI.
=95 Preliminary/preclinical data are required, indicating potential
substantial benefit for veterans with GWI.
=95 Pilot or exploratory studies focusing on treatments lacking
preclinical/preliminary data should submit to the Innovative Treatment
Evaluation Award.
=95 The maximum allowable funding for the entire period of performance
is $1,400,000 for direct costs.
=95 Indirect costs may be proposed in accordance with the institution=92s
negotiated rate agreement.
=95 The maximum period of performance is 4 years.
=95 More cost-effective studies not requesting the full funding amount
are encouraged.
ALL: All applications must conform to the final program announcements
and application instructions that are available for electronic
downloading from theGrants.gov website. The application package
containing the required forms for each award mechanism can also be
found by clicking the hyperlinked award mechanism titles, above. A
listing of all USAMRMC funding opportunities can be obtained on the
Grants.gov website by performing a basic search using CFDA Number
12.420. Funding opportunities for breast cancer, ALS, and bone marrow
failure medical research are also available at this link.
A pre-application is required and must be submitted through the CDMRP
eReceipt website (http://cdmrp.org) prior to the pre-application
deadline of April 9, 2012. Applications must be submitted through the
federal government=92s single-entry portal, Grants.gov.
Requests for email notification of the program announcements release
may be sent to help@cdmrp.org. For more information about the GWIRP or
other CDMRP-administered programs, please visit the CDMRP website
(http://cdmrp.army.mil).
For additional information regarding eligibility, application
submission, and questions about the program itself please contact the
CDMRP helpdesk at help@CDMRP.org or call (301) 682-5507.
If you would like to request direct email messages from CDMRP, please
contact CDMRP.PublicAffairs@amedd.army.mil with your email address.
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
